2024-07-02 00:25:03
Endometrial cancer is the most common gynecological cancer in developed countries, with approximately 417,000 new cases reported each year worldwide. The European Commission’s authorization for this first-line drug took place in December last year.
It is now in Spain JEMPERLI (dostarlimab) in combination with carboplatin and paclitaxel (chemotherapy), for the treatment of elderly patients with newly diagnosed or advanced breast cancer with a deficient replication mechanism (dMMR)/high microsatellite instability (MSI- H) and they are candidates for the disability program. In this way, a new monoclonal antibody that inhibits the receptor of programmed cell death protein 1 (PD-1) and which is already available in our country since April of last year (but only for patients of their disease has progressed) during or after platinum before. -based treatment), is now the first and first-line immuno-oncological treatment for endometrial cancer in Spain.
Regional Director of Oncohematology at GSK in Spain, Sergio Ostalé, explains: “Until now, most women with advanced endometrial cancer will experience disease progression due to poor long-term results of treatment. also offered. With the presence of this novel treatment on the front line, the number of patients who can benefit from this drug in Spain is increasing, including women whose disease is at an earlier stage. Dostarlimab is a drug that continues to change the treatment landscape of endometrial cancer, now also in the first line of treatment. “It is a promising drug to become a key immuno-oncology therapy in the treatment of cancer.” And he added that “Our goal is to continue to identify ways to use dostarlimab in monotherapy and in combination with other treatments to help improve outcomes for patients with limited treatment options in these another tumor.”
Endometrial cancer is the most common gynecological cancer in developed countries, with approximately 417,000 new cases reported each year worldwide and incidence rates are expected to increase by nearly 40% by 2020. and 2040. In Spain it is the fourth most common tumor in women, with 7,305 new cases estimated for 2024.
Dr. Antonio González, director of the Department of Oncology at the Clínica Universidad de Navarra and president of the Spanish Gynecological Cancer Research Association (GEICO), added: “It is very good news to receive this treatment included. Spain, since I believe it will define a new treatment standard for certain patients with advanced or relapsed endometrial cancer in our country. The results of the RUBY study, which led to first-line approval, demonstrate the ability of this drug to change clinical practice in these patients and recent data show that this drug helps patients improve and not predict disease. them and quality of life, but also increase overall survival. “
The authorization of the European Commission of this drug in the first line took place in December last year and is based on the results of the interim analysis of part 1 of phase III RUBY/ENGOT-EN6/GOG3031/NSGO in the dMMR/ population. MSI-H, with a strong median follow-up duration of ≥25 months. The trial met its primary endpoint of investigator progression-free survival (PFS), demonstrating statistically significant and clinical benefit in patients treated with dostarlimab plus carboplatin and paclitaxel in the dMMR/ MSI-H. In this population, a 72% reduction in the risk of disease progression or death was observed compared with chemotherapy alone (HR: 0.28 [IC 95 %: 0,16-0,50]). In a prespecified subgroup analysis of overall survival (OS) in the dMMR/MSI-H population, the addition of dostarlimab to chemotherapy demonstrated a 68% reduction in the risk of death compared with chemotherapy alone (HR: 0.32). [IC del 95 %: 0,17–0,63]).
The safety and tolerability profile of dostarlimab in combination with carboplatin and paclitaxel is generally consistent with the known safety profiles of these drugs at the individual level. The most common adverse reactions (≥10%) in patients receiving this combination are rash, hypothyroidism (underactive thyroid), alanine aminotransferase or aspartate aminotransferase increase (increased levels of liver enzymes in the blood ), pyrexia (fever) and dry skin.
About endometrial cancer
Endometrial cancer occurs in the lining of the uterus, known as the endometrium. It is the most common gynecological cancer in developed countries, with approximately 417,000 new cases reported each year worldwide1 and incidence rates are expected to increase by almost 40% between the years 2020 and 2040. Approximately 15 to 20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis. LDB (SyM)
#immunooncological #financial #treatment #firstline #treatment #endometrial #cancer #Spain